Silexion Therapeutics Stays Listed on Nasdaq After Appeal

Silexion Therapeutics ( (SLXN) ) has issued an update.

On July 7, 2025, Silexion Therapeutics received a favorable decision from a Nasdaq hearings panel, allowing the company to remain listed on Nasdaq, subject to certain conditions. The decision follows a hearing on June 26, 2025, where Silexion appealed a delisting notice due to listing deficiencies. The company’s shares and warrants will be transferred to the Nasdaq Capital Market, contingent on meeting a compliance plan aimed at achieving $2.5 million in shareholders’ equity by September 19, 2025. Silexion also plans a 1-for-15 reverse share split to address a potential bid price deficiency, pending shareholder approval at the reconvened annual general meeting on July 14, 2025.

The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics Corp is a company based in the Cayman Islands, operating in the biotechnology industry. The company focuses on developing therapeutic solutions and is listed on the Nasdaq Stock Market.

Average Trading Volume: 1,665,178

Technical Sentiment Signal: Sell

Current Market Cap: $7.08M

Learn more about SLXN stock on TipRanks’ Stock Analysis page.